Clinical trial
Phase I/II Trial of Weekly Motexafin Gadolinium (MGd) for Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00290004 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I/II Trial of Weekly Motexafin Gadolinium (MGd) for Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Lead sponsor
- Pharmacyclics LLC.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 30, 2005
- Completion date
- February 28, 2007
- Enrollment
- 35
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.